Key result
Nanoparticle drug delivery enables targeted therapeutic release to promote atherosclerotic plaque resolution.
Answers are grounded in this paper and cite their sources.
Atherosclerosis is the build-up of fatty deposits in the arteries, which is the main underlying cause of cardiovascular diseases and the leading cause of global morbidity and mortality. Current pharmaceutical treatment options are unable to effectively treat the plaque in the later stages of the disease. Instead, they are aimed at resolving the risk factors. Nanomaterials and nanoparticle-mediated therapies have become increasingly popular for the treatment of atherosclerosis due to their targeted and controlled release of therapeutics. In this review, we discuss different types of therapeutics used to treat this disease and focus on the different nanomaterial strategies employed for the delivery of these drugs, enabling the effective and efficient resolution of the atherosclerotic plaque. The ideal nanomaterial strategy for each drug type (e.g. statins, nucleic acids, small molecule drugs, peptides) will be comprehensively discussed.
No takes yet. Share an insight, caveat, or question.
Perera et al. (2023) conducted a review in Atherosclerosis. Nanomaterial and nanoparticle-mediated drug delivery systems (for statins, nucleic acids, small molecule drugs, peptides) was evaluated on Resolution of atherosclerotic plaque. Nanomaterial and nanoparticle-mediated drug delivery strategies enable targeted, controlled release of therapeutics (e.g., statins, nucleic acids, peptides) to resolve atherosclerotic plaques.
Synapse has enriched 10 related papers. Consider them for comparative context: